HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA IN RELATION TO LINE OF TREATMENT AND RESPONSE
(Abstract release date: 05/19/16)
EHA Library. Hu H. 06/09/16; 133008; E1459
Dr. Henry Hu
Contributions
Contributions
Abstract
Abstract: E1459
Type: Eposter Presentation
Background
Health-related quality of life (HRQoL) in patients with multiple myeloma (MM) has mostly been evaluated in controlled trials composed of largely homogeneous patient populations. There is a paucity of literature examining HRQoL in patients with MM at different treatment stages in a real-world setting.
Aims
To document and compare self-reported HRQoL outcomes in patients with MM across different lines of treatment and response status.
Methods
US patients with self-reported MM were recruited through an online patient-powered network, PatientsLikeMe. Upon completion of informed consent, study participants were asked to provide their MM treatment history and complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). HRQoL scores were compared using the Kruskal-Wallis test across the following subgroups: patients who had received stem cell transplant (SCT); patients who had not switched their drug regimens as a result of disease progression; patients who had 1-3 drug regimen switches because of disease progression; and patients who had ≥ 4 switches because of disease progression. HRQoL domain scores were also compared across subgroups based on response status reported to patients at their last provider visit (complete response, partial response/under control/stable, relapse/recurred or not responsive/progressive disease) irrespective of treatment lines.
Results
A total of 199 patients completed the online survey. Of these, 10 patients were excluded from this analysis because they had not received any MM treatment. Of the remaining 189 patients, the median age was 61 years (range, 37-82 years) and 57.6% were women. 58 patients reported receiving SCT, 66 patients reported not switching treatment regimens because of disease progression, 43 patients reported 1-3 switches because of disease progression, and 22 reported ≥ 4 switches because of disease progression. Global HRQoL domain scores varied from 58.3 to 68.7 (P = .279) as measured by the EORTC QLQ-C30. Comparable HRQoL in other domains were also reported across different treatment lines. Patients reporting their most recent response status as “complete response” had the highest Global HRQoL score (71.7) relative to patients reporting their most recent status as “partial response/under control or stable” (63.0) or “relapsed/recurred or not responsive/progressive disease” (55.6; P = .012). Similarly, statistically significant higher HRQoL scores were reported in the Physical Functioning, Social Functioning, and Pain domains in patients who experienced complete responses.
Conclusion
Domains of Global HRQoL, Physical Functioning, Social Functioning, and Pain in patients with MM treated in usual care settings were associated with their response status.
Session topic: E-poster
Type: Eposter Presentation
Background
Health-related quality of life (HRQoL) in patients with multiple myeloma (MM) has mostly been evaluated in controlled trials composed of largely homogeneous patient populations. There is a paucity of literature examining HRQoL in patients with MM at different treatment stages in a real-world setting.
Aims
To document and compare self-reported HRQoL outcomes in patients with MM across different lines of treatment and response status.
Methods
US patients with self-reported MM were recruited through an online patient-powered network, PatientsLikeMe. Upon completion of informed consent, study participants were asked to provide their MM treatment history and complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). HRQoL scores were compared using the Kruskal-Wallis test across the following subgroups: patients who had received stem cell transplant (SCT); patients who had not switched their drug regimens as a result of disease progression; patients who had 1-3 drug regimen switches because of disease progression; and patients who had ≥ 4 switches because of disease progression. HRQoL domain scores were also compared across subgroups based on response status reported to patients at their last provider visit (complete response, partial response/under control/stable, relapse/recurred or not responsive/progressive disease) irrespective of treatment lines.
Results
A total of 199 patients completed the online survey. Of these, 10 patients were excluded from this analysis because they had not received any MM treatment. Of the remaining 189 patients, the median age was 61 years (range, 37-82 years) and 57.6% were women. 58 patients reported receiving SCT, 66 patients reported not switching treatment regimens because of disease progression, 43 patients reported 1-3 switches because of disease progression, and 22 reported ≥ 4 switches because of disease progression. Global HRQoL domain scores varied from 58.3 to 68.7 (P = .279) as measured by the EORTC QLQ-C30. Comparable HRQoL in other domains were also reported across different treatment lines. Patients reporting their most recent response status as “complete response” had the highest Global HRQoL score (71.7) relative to patients reporting their most recent status as “partial response/under control or stable” (63.0) or “relapsed/recurred or not responsive/progressive disease” (55.6; P = .012). Similarly, statistically significant higher HRQoL scores were reported in the Physical Functioning, Social Functioning, and Pain domains in patients who experienced complete responses.
Conclusion
Domains of Global HRQoL, Physical Functioning, Social Functioning, and Pain in patients with MM treated in usual care settings were associated with their response status.
Session topic: E-poster
Abstract: E1459
Type: Eposter Presentation
Background
Health-related quality of life (HRQoL) in patients with multiple myeloma (MM) has mostly been evaluated in controlled trials composed of largely homogeneous patient populations. There is a paucity of literature examining HRQoL in patients with MM at different treatment stages in a real-world setting.
Aims
To document and compare self-reported HRQoL outcomes in patients with MM across different lines of treatment and response status.
Methods
US patients with self-reported MM were recruited through an online patient-powered network, PatientsLikeMe. Upon completion of informed consent, study participants were asked to provide their MM treatment history and complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). HRQoL scores were compared using the Kruskal-Wallis test across the following subgroups: patients who had received stem cell transplant (SCT); patients who had not switched their drug regimens as a result of disease progression; patients who had 1-3 drug regimen switches because of disease progression; and patients who had ≥ 4 switches because of disease progression. HRQoL domain scores were also compared across subgroups based on response status reported to patients at their last provider visit (complete response, partial response/under control/stable, relapse/recurred or not responsive/progressive disease) irrespective of treatment lines.
Results
A total of 199 patients completed the online survey. Of these, 10 patients were excluded from this analysis because they had not received any MM treatment. Of the remaining 189 patients, the median age was 61 years (range, 37-82 years) and 57.6% were women. 58 patients reported receiving SCT, 66 patients reported not switching treatment regimens because of disease progression, 43 patients reported 1-3 switches because of disease progression, and 22 reported ≥ 4 switches because of disease progression. Global HRQoL domain scores varied from 58.3 to 68.7 (P = .279) as measured by the EORTC QLQ-C30. Comparable HRQoL in other domains were also reported across different treatment lines. Patients reporting their most recent response status as “complete response” had the highest Global HRQoL score (71.7) relative to patients reporting their most recent status as “partial response/under control or stable” (63.0) or “relapsed/recurred or not responsive/progressive disease” (55.6; P = .012). Similarly, statistically significant higher HRQoL scores were reported in the Physical Functioning, Social Functioning, and Pain domains in patients who experienced complete responses.
Conclusion
Domains of Global HRQoL, Physical Functioning, Social Functioning, and Pain in patients with MM treated in usual care settings were associated with their response status.
Session topic: E-poster
Type: Eposter Presentation
Background
Health-related quality of life (HRQoL) in patients with multiple myeloma (MM) has mostly been evaluated in controlled trials composed of largely homogeneous patient populations. There is a paucity of literature examining HRQoL in patients with MM at different treatment stages in a real-world setting.
Aims
To document and compare self-reported HRQoL outcomes in patients with MM across different lines of treatment and response status.
Methods
US patients with self-reported MM were recruited through an online patient-powered network, PatientsLikeMe. Upon completion of informed consent, study participants were asked to provide their MM treatment history and complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). HRQoL scores were compared using the Kruskal-Wallis test across the following subgroups: patients who had received stem cell transplant (SCT); patients who had not switched their drug regimens as a result of disease progression; patients who had 1-3 drug regimen switches because of disease progression; and patients who had ≥ 4 switches because of disease progression. HRQoL domain scores were also compared across subgroups based on response status reported to patients at their last provider visit (complete response, partial response/under control/stable, relapse/recurred or not responsive/progressive disease) irrespective of treatment lines.
Results
A total of 199 patients completed the online survey. Of these, 10 patients were excluded from this analysis because they had not received any MM treatment. Of the remaining 189 patients, the median age was 61 years (range, 37-82 years) and 57.6% were women. 58 patients reported receiving SCT, 66 patients reported not switching treatment regimens because of disease progression, 43 patients reported 1-3 switches because of disease progression, and 22 reported ≥ 4 switches because of disease progression. Global HRQoL domain scores varied from 58.3 to 68.7 (P = .279) as measured by the EORTC QLQ-C30. Comparable HRQoL in other domains were also reported across different treatment lines. Patients reporting their most recent response status as “complete response” had the highest Global HRQoL score (71.7) relative to patients reporting their most recent status as “partial response/under control or stable” (63.0) or “relapsed/recurred or not responsive/progressive disease” (55.6; P = .012). Similarly, statistically significant higher HRQoL scores were reported in the Physical Functioning, Social Functioning, and Pain domains in patients who experienced complete responses.
Conclusion
Domains of Global HRQoL, Physical Functioning, Social Functioning, and Pain in patients with MM treated in usual care settings were associated with their response status.
Session topic: E-poster
{{ help_message }}
{{filter}}